Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany,
Center for Molecular Medicine (CMMC) University of Cologne, Cologne, Germany,
Ophthalmic Res. 2021;64(2):145-167. doi: 10.1159/000509954. Epub 2020 Jul 7.
To discuss and evaluate new technologies for a better diagnosis of corneal diseases and limbal stem cell deficiency, the outcomes of a consensus process within the European Vision Institute (and of a workshop at the University of Cologne) are outlined. Various technologies are presented and analyzed for their potential clinical use also in defining new end points in clinical trials. The disease areas which are discussed comprise dry eye and ocular surface inflammation, imaging, and corneal neovascularization and corneal grafting/stem cell and cell transplantation. The unmet needs in the abovementioned disease areas are discussed, and realistically achievable new technologies for better diagnosis and use in clinical trials are outlined. To sum up, it can be said that there are several new technologies that can improve current diagnostics in the field of ophthalmology in the near future and will have impact on clinical trial end point design.
为了讨论和评估用于更好地诊断角膜疾病和角膜缘干细胞缺乏症的新技术，概述了欧洲视觉研究所（以及科隆大学研讨会）内的共识过程的结果。介绍了各种技术，并分析了它们在临床试验中定义新终点的潜在临床用途。讨论的疾病领域包括干眼和眼表面炎症、成像以及角膜新生血管形成和角膜移植/干细胞和细胞移植。讨论了上述疾病领域中未满足的需求，并概述了在可实现的新技术，以更好地诊断和临床试验中的应用。总之，可以说，在不久的将来，有几种新技术可以改善眼科领域的当前诊断，并将对临床试验终点设计产生影响。
